A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Phase 1 Completed 71 enrolled Pfizer Bristol-Myers Squibb · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses of PF-04620110.

Timeline

Start: 2009-08
Primary completion: 2010-05
Completion: 2010-05

Publications

Amin NB, Saxena AR, Somayaji V, Dullea R. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology. Clin Ther. 2023 Jan;45(1):55-70. doi: 10.1016/j.clinthera.2022.12.008. Epub 2023 Jan 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-04620110	Small molecule	1 mg	Oral
Subject	PF-04620110	Small molecule	3 mg	Oral
Subject	PF-04620110	Small molecule	5 mg	Oral
Subject	PF-04620110	Small molecule	10 mg	Oral
Subject	PF-04620110	Small molecule	20 mg	Oral

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Summary

Timeline

Publications

Drugs

Indications